Pulmonology

 
Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma
May 16, 2022

ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.

Factors Linked to Switching Biologic Treatments in Patients with Severe Asthma
March 23, 2022

Higher blood eosinophils, younger age, and eosinophilic chronic rhinosinusitis were among factors associated with a switch from initial biologic therapy in a new study.

FDA Approves First Generic of Symbicort Inhaler to Treat Asthma, COPD
March 16, 2022

The FDA has approved the first generic budesonide and formoterol fumarate dihydrate inhalation aerosol for the treatment of asthma and COPD.

Mepolizumab Clinically Effective Regardless of Type 2 Biomarker Status in Patients with Severe Asthma, Suggests Real-world Data
February 28, 2022

AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.

Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis
February 26, 2022

AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.

Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria
February 26, 2022

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Racial/Ethnic Bias Found in Asthma Clinical Trials Used to Update NHLBI Guideline
February 22, 2022

In the majority of studies that reported racial/ethnic data, White participants were highly overrepresented and Black/Hispanic/all Other underrepresented.

Tezepelumab Reduced Number of Symptomatic Days in Adults and Children with Severe, Uncontrolled Asthma
February 17, 2022

Patients with severe, uncontrolled asthma given tezepelumab experienced a reduction in asthma symptomatic days, found a new analysis of the NAVIGATOR trial.

Tezepelumab Found Effective in Reducing Exacerbations in Moderate-to-Severe, Uncontrolled Asthma
February 11, 2022

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

New Study Identifies Key Risk Factors Likely to Accelerate a COPD Diagnosis in Patients with Asthma
February 08, 2022

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.